Dr Van Gorp on the Long-Term Efficacy of Mirvetuximab Soravtansine in FRα+ Platinum-Resistant Ovarian Cancer
March 16th 2025
Toon Van Gorp, MD, PhD, discusses the efficacy of mirvetuximab soravtansine in FRα-positive platinum-resistant ovarian cancer after 30.5 months of follow-up.